Sign in →

Test Code NGPLSC OncoPlus, Universal Cancer Mutation Analysis Panel (NGS), (Cytology Smear)

Important Note

Starting on 01/09/2017, the University of Chicago Molecular Pathology Laboratory launched an updated version of the OncoPlus universal cancer mutation analysis panel. This is a Next Generation Sequencing assay designed to interrogate over 1,200 solid tumor and hematological malignancy related genes via analysis of Peripheral Blood, Bone Marrow, Formalin-Fixed Paraffin-Embedded and Cytology Smear specimens. 28 additional genes were added to the previously 119 clinically reported genes.

In addition, this updated panel version allows:

  • The detection and reporting of copy number variations (CNVs) for 136 genes.
  • The detection and reporting of lung cancer-related gene fusions in ALK, RET, and ROS1.

Specimen and Container/Tube

Cytology Smear

Rejection Criteria

>72 hours

Turnaround Time

Not Available

Specimen Type

Cytology Smear

Preferred Volume

10 Slides

Offsite Collection Instructions

Send within 72 hours

UCMC Collection Instructions

Send within 72 hours

Test Usage

Comprehensive assay for cancer genomic of solid tumor and
hematological malignancy specimens to determine appropriate
therapies. It also can be useful for diagnosis, prognosis,
clinical
trials selection and for translational research.

Additional Information

  • Appropriate specimens (FFPE) should
    contain >20% tumor cells
    and enough total cells to produce adequate DNA yield (typically
    >50,000 total cells).
  • Specimens with less than 20% tumor cells may be tested at
    the
    discretion of the attending molecular pathologist.
  • Specimens fixed or decalcified in mercury-based fixatives
    such
    as B5 are unacceptable. Other fixatives will be accepted at the
    discretion of the laboratory director.
  • Unstained slides containing formalin-fixed, paraffin
    embedded
    tissue are acceptable. At least 10 microtome sections of 5
    micron
    thickness should be submitted for testing.?�

Test Limitations

Will not detect mutations below the analytical sensitivity
of
the assay (10% variant allelic frequency). For detection of
FGFR1/2/3 and NTRK1/2/3 fusions, please order separate RNA Gene Fusion Panel.

Critical Results

None

Fee Code

376540-30181445

STAT Turnaround Time

Not Available

Container/Tube

Unstained Cytology Smear Slides

Specimen Minimum Volume

5 Slides

Special Instructions

Send within 72 hours

Day(s) Performed

Monday – Friday, 8:00 AM – 4:30 PM

STAT DAY(S) AND TIME(S) PERFORMED

No

CPT

81445

Method Name

Next Generation Sequencing

Reference Values

Interpretative report

Reject Due To

>72 hours

Pediatric Volume

5 Slides

Clinical Indications

Comprehensive assay for cancer genomic of solid tumor and
hematological malignancy specimens to determine appropriate
therapies. It also can be useful for diagnosis, prognosis,
clinical
trials selection and for translational research.

Transport Instructions

Send within 72 hours

Methodology

Next Generation Sequencing